{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"64.0","value":"7.46"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"60.1","value":"8.64"},{"groupId":"OG002","lowerLimit":"0.7","upperLimit":"56.9","value":"11.30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"101"}],"units":"Participants"}],"description":"Overall survival is defined as the time from the date of first dose of study drug to the date of the participant's death from any cause.","dispersionType":"Full Range","groups":[{"description":"Participants received single dose of erdafitinib 10 mg tablet, orally, once daily, starting from Day 1 through Day 7 and from Day 15 through Day 21 and so on, that is 7-day on and off in each subsequent 28-day cycles starting from Cycle 1. Based on serum phosphate (PO4) levels, there was an option to up-titrate erdafitinib dose to 12 mg, orally, once daily starting from Cycle 2 Day 1 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG000","title":"Main Study: Regimen 1: Erdafitinib 10 Milligrams (mg)/ 12 mg"},{"description":"Participants received single dose of erdafitinib 6 mg tablet, orally, once daily, starting from Day 1 through Day 28 in each subsequent 28-day cycles starting from Cycle 1. Based on serum PO4 levels, there was an option to up-titrate erdafitinib dose to 8 mg, orally, once daily starting from Cycle 2 Day 1 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG001","title":"Main Study: Regimen 2: Erdafitinib 6 mg/ 8 mg"},{"description":"Participants received single dose of erdafitinib 8 mg tablet, orally, once daily, starting from Day 1 through Day 28 in each subsequent 28-day cycles starting from Cycle 1. Based on serum PO4 levels, there was an option to up-titrate erdafitinib dose to 9 mg, orally, once daily starting from Cycle 1 Day 15 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG002","title":"Main Study: Regimen 3: Erdafitinib 8 mg/ 9 mg"}],"paramType":"MEDIAN","populationDescription":"The population included participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From screening up to 6 years 2 months","title":"Main Study: Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}